Insight

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah and Vania Hungria

Oct 26, 2024, 12:33

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University of Kansas Medical Center, shared an article by Vania Hungria, Department of hematology at Santa Casa de São Paulo, on X:

” Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?”

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Authors: Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, D.Phil and Ana Carolina Ribas de Almeida

Al-Ola A Abdallah

Al-Ola A Abdallah Ana Carolina Ribas de Almeida cancer Christopher Ward combination therapy D.Phil Marek Hus Myeloma OncoDaily Oncology P. Joy Ho Pawel Robak Santa Casa de São Paulo University of Kansas Medical Center Vania Hungria Vera Zherebtsova

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage